sorafenib has been researched along with n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide in 8 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide) | Trials (n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide) | Recent Studies (post-2010) (n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 30 | 5 | 26 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K | 1 |
| Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH | 1 |
| Barone, M; Carr, BI; Di Leo, A; Facciorusso, A; Licinio, R | 1 |
| Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT | 1 |
| Blanc, JF; Childs, BH; Choo, SP; Dao, T; Dufour, JF; Gane, EJ; Gérolami, R; Kocsis, J; Krissel, H; Lamlertthon, W; Lim, HY; Llovet, JM; Ma, YT; Mazzaferro, V; Merle, P; Peck-Radosavljevic, M; Reis, D; Ross, P; Roth, K; Ryoo, BY; Sukeepaisarnjaroen, W; Teufel, M; Thongsawat, S; Weiss, KH; Yau, T; Yen, CJ; Yeo, W | 1 |
| Das, M | 1 |
| Goh, KY; Huynh, H; Lee, LY; Mumberg, D; Ong, R; Politz, O; Puehler, F; Scholz, A; Ziegelbauer, K | 1 |
1 review(s) available for sorafenib and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2015 |
3 trial(s) available for sorafenib and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Carcinoma, Hepatocellular; Diphenylamine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides; Treatment Outcome | 2014 |
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Diphenylamine; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2016 |
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Carcinoma, Hepatocellular; Circulating Tumor DNA; Diphenylamine; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Middle Aged; Mutation; Protein Kinase Inhibitors; ras Proteins; Sorafenib; Sulfonamides; Telomerase; Tumor Suppressor Protein p53 | 2018 |
4 other study(ies) available for sorafenib and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Topics: Allografts; Allosteric Regulation; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diphenylamine; Drug Synergism; Female; Heterografts; Humans; Liver Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Sulfonamides | 2013 |
Refametinib in RAS-mutated hepatocellular cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Diphenylamine; Humans; Liver Neoplasms; Mutation; ras Proteins; Sorafenib; Sulfonamides | 2018 |
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Sorafenib; Sulfonamides; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |